BYSINasdaqPharmaceutical PreparationsFiscal year ends December 31
BeyondSpring Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.51−0.05 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $21.09M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -113.8% | -102.8% | 3.1% | |
| Return on assets | -92.8% | -75.5% | -3.3% | |
| Current ratio | 5.64 | 8.24 | 1.54 | |
| Debt to equity | – | 0.02 | – | |
| Interest coverage | – | -755.4× | – | |
| Capex to revenue | – | 28.9% | – | |
| Diluted shares | 16M | 30M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
BeyondSpring generated $128.08M from operations and spent $3.25M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$128.08M
Used
$3.25M
Capital expenditure$3.25M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2463.3%
×Asset turnover0.02×
×Equity multiplier6.18×
=Return on equity, FY2022-321.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -2463.3% | 0.02× | 6.18× | -321.5% |
| FY2021 | -4750.5% | 0.01× | 1.73× | -111.6% |
| FY2020 | -33873.9% | 0.00× | 1.36× | -102.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$1.01M
- Cash generatingOperating cash flow above zero-$19.77M
- Return on assets improvedROA up on the prior year-44.8% → -2.9%
- Earnings backed by cashOperating cash flow above net income-$19.77M vs -$1.01M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.60 → 1.54
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00